The Gray Zone: How 503B Pharmacies Navigate the Intersection of FDA Regulation and Drug Patents
In pharmaceuticals 503B outsourcing facilities occupy a unique and often contentious space. Born from the ashes of a public health […]
More Biopharmaceutical Competition, Better Products: Evidence From Tariff Cuts
On one hand, the pharmaceutical sector is driven by a scientific and economic imperative that thrives on openness: the seamless
More Biopharmaceutical Competition, Better Products: Evidence From Tariff Cuts Read Post »
Uncovering the Hidden Financial, Strategic, and Operational Risks of Contesting Big Pharma Patents
I. Introduction: Beyond the Courtroom – The Real Stakes of a Patent Challenge In the high-stakes world of pharmaceuticals, the
The Repurposing Revolution: Unlocking Hidden Value in Pharmaceutical Patents
Introduction: Beyond Serendipity – The New Strategic Imperative For decades, the pharmaceutical industry has operated on a model of heroic,
The Repurposing Revolution: Unlocking Hidden Value in Pharmaceutical Patents Read Post »
Russian Pharmaceuticals: An Overview of a Growing Global Market
The Russian pharmaceutical industry presents a formidable paradox. On one hand, it is a vast, multi-trillion-rouble arena demonstrating robust growth
Russian Pharmaceuticals: An Overview of a Growing Global Market Read Post »
The CIS Generic Market Playbook: Strategies for Leadership in a Fragmented and Evolving Landscape
Section 1: The CIS Pharmaceutical Arena: A Market of Contrasts and Opportunities The pharmaceutical landscape of the Commonwealth of Independent
The Brazilian Recipe: Inside the Success Story of a Homegrown Pharmaceutical Powerhouse
Executive Summary The ascent of Brazil’s pharmaceutical giants represents one of the most compelling success stories in emerging market industrial
The Brazilian Recipe: Inside the Success Story of a Homegrown Pharmaceutical Powerhouse Read Post »
Navigating the Intellectual Property Minefield: A Strategic Guide to Mitigating Patent Litigation Risks in M&A Due Diligence
Why Pharma M&A Is Really a Patent Acquisition Business When AstraZeneca paid $39 billion for Alexion in 2021, it wasn’t
A Strategic Guide to Capitalizing on Patent Expiry, Generic Entry, and Product Reformulation
The patent cliff is measurable, foreseeable, and still consistently underestimated. Between 2025 and 2030, the U.S. pharmaceutical market will surrender
